South Korea's SK Bioscience has agreed to produce AstraZeneca's experimental COVID-19 vaccine to help the British firm build global supplies of the vaccine, which has shown promise against the virus.
SK Bioscience, AstraZeneca and South Korea's health ministry on Tuesday signed a letter of intent with three major goals.
The goals are ensuring fast and stable production and exports, boosting production capacity to cope with demand, and lastly, securing a domestic supply.
The local bio-firm will supply the ADZ1222 material, which has generated keen global interest, for being the first vaccine material given permission for phase-3 clinical tests.
SK Bioscience says production will take place at its vaccine factory in Andong, Gyeongsangbuk-do Province, after fixing manufacturing plans with AstraZeneca.